Clinical Trials for Liver Cancer

A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with unresectable, locally advanced, or metastatic solid tumors who have exhausted standard therapies, good performance status (ECOG 0-1), and adequate organ function. The investigational agent is AGX101, a TM4SF1-targeted antibody-drug conjugate delivering a maytansinoid payload to tumor and tumor vasculature cells.

ClinicalTrials.gov ID: NCT06440005

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced unresectable or metastatic solid tumors (including a broad range such as ovarian, pancreatic, GI, lung, and more) or relapsed/refractory multiple myeloma who have failed or are intolerant to standard therapies are eligible to receive QXL138AM, a masked anti-CD138 immunocytokine fused to interferon alpha-2a designed for tumor-targeted immune activation.

ClinicalTrials.gov ID: NCT06582017

A Phase I/II Trial of Cabozantinib in Combination with Durvalumab (MEDI4736) with or Without Tremelimumab in Patients with Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with ECOG 0–1 and advanced/unresectable gastric/GEJ or esophageal adenocarcinoma (post ≥1 line), colorectal adenocarcinoma (post ≥2 lines; anti-EGFR if RAS WT), or hepatocellular carcinoma (treatment‑naive or previously treated) receive cabozantinib (MET/VEGFR2/AXL multikinase inhibitor) plus durvalumab (PD‑L1 inhibitor), with an HCC cohort also getting a single priming dose of tremelimumab (CTLA‑4 antibody). Baseline/on‑treatment biopsies required; prior PD‑1/PD‑L1 generally excluded except per HCC and gastric/esophageal protocol allowances.

ClinicalTrials.gov ID: NCT03539822

Interleukin-15 Armored Glypican-3-specific Chimeric Antigen Receptor Expressing Autologous T Cells as Immunotherapy for Patients With SOLID TUMORS (CATCH)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory GPC3-positive solid tumors (including HCC meeting BCLC A–C and Child-Pugh <7) receive lymphodepleting cyclophosphamide/fludarabine followed by a single infusion of autologous GPC3-targeted CAR T cells engineered to express IL-15 for enhanced persistence and an inducible caspase-9 safety switch. Key exclusions include prior organ transplant, uncontrolled infection, HIV, pregnancy, high-dose steroids at infusion, and murine protein hypersensitivity/HAMA.

ClinicalTrials.gov ID: NCT05103631

Phase 2 Study of Cabozantinib Combined With Ipilimumab/Nivolumab and Transarterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma (HCC) Who Are Not Candidates for Curative Intent Treatment

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable HCC not eligible for curative therapy (Child-Pugh A/B7, ECOG 0–2) and at least one TACE-amenable lesion receive TACE (up to 3 sessions) plus a single priming dose of nivolumab/ipilimumab followed by maintenance nivolumab and cabozantinib 40 mg daily. Cabozantinib is a multi–tyrosine kinase inhibitor (MET/VEGFR2/AXL) combined here with PD‑1 and CTLA‑4 blockade to enhance locoregional and systemic antitumor activity.

ClinicalTrials.gov ID: NCT04472767

A Phase I/II Study of Nivolumab Plus 5-Fluorouracil Plus Interferon-α2b for Unresectable Fibrolamellar Hepatocellular Carcinoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Single-center, single-arm study for adolescents and adults with unresectable fibrolamellar HCC, ECOG 0–1 and Child-Pugh A, excluding prior PD-1 for FLHCC and active autoimmune/hepatitis. Patients receive 5-FU plus interferon-α2b with nivolumab (anti–PD-1 checkpoint inhibitor) added from cycle 3, continuing in 28-day cycles up to 2 years to assess safety and preliminary efficacy, including potential conversion to resection.

ClinicalTrials.gov ID: NCT04380545

A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, metastatic, or unresectable solid tumors or relapsed/refractory hematologic malignancies without standard options, including cohorts with normal, moderate, or severe hepatic impairment, receive oral tazemetostat 800 mg (EZH2 histone methyltransferase inhibitor) with PK-intensive sampling. Continued twice-daily dosing in 28-day cycles is allowed until progression or intolerance.

ClinicalTrials.gov ID: NCT04241835

Study of Intratumoral Injection of Dendritic Cells After High-Dose Conformal External Beam Radiotherapy in Patients With Unresectable Liver Cancer

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable primary liver cancer confined to the liver (ECOG 0–1) receive high-dose conformal EBRT followed by intratumoral autologous dendritic cell injections (with intramuscular Prevnar as an immune adjuvant); tumors must be accessible for ultrasound-guided injection. The HCC cohort also adds atezolizumab (anti–PD‑L1) plus bevacizumab (anti‑VEGF) to the DC/EBRT regimen.

ClinicalTrials.gov ID: NCT03942328

A Phase 1, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors and ECOG 0–2, including a cohort with moderate hepatic impairment (bilirubin >1.5×–≤3× ULN), receive sacituzumab govitecan-hziy (Trop-2–targeted ADC delivering SN-38) on Days 1 and 8; dose-escalation (5→7.5→10 mg/kg) is tested in the impaired-liver cohort with a normal-liver comparator at 10 mg/kg. Excludes recent irinotecan, active CNS disease, Gilbert’s syndrome, strong UGT1A1 modulators, and significant liver-related complications in the impaired cohort.

ClinicalTrials.gov ID: NCT04617522

A Phase 1 Study of Combined Y-90 Selective Internal Radiation Therapy (Y-90 SIRT) and Stereotactic Body Radiation Therapy (SBRT) in Hepatic Malignancy.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable hepatocellular carcinoma or liver-only metastases receive Y-90 radioembolization (TheraSphere) followed by PET-CT–guided SBRT boost to underdosed tumor regions, with strict liver function and no progressive extrahepatic disease required. Aims to assess hepatic decompensation risk and early local control using adaptive dosimetry.

ClinicalTrials.gov ID: NCT04518748